VANGUARD CPV
Country: Ireland
Bahasa: Inggeris
Sumber: HPRA (Health Products Regulatory Authority)
Ciri produk
(SPC)
26-05-2024
Beberapa dokumen untuk produk ini saat ini tidak tersedia, anda dapat mengirim permintaan ke layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami dapat memperolehnya.
Hantar permintaan.
Hantar permintaan.
Bahan aktif:
CANINE PARVOVIRUS, STRAIN NL-35-D, LIVE ATTENUATED
Boleh didapati daripada:
Pfizer Healthcare Ireland
Kod ATC:
QI07AD01
Borang farmaseutikal:
Solution for Injection
Kumpulan terapeutik:
Immunological - Live Vaccine
Kawasan terapeutik:
Canine
Tarikh kebenaran:
2004-05-28
Ciri produk
IRISH MEDICINES BOARD ACT 1995, AS AMENDED
EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (NO. 2) REGULATIONS 2007
VPA: 10019/072/001
Case No: 7007027
The Irish Medicines Board in exercise of the powers conferred on it by Animal Remedies (No. 2) Regulations (S.I. No. 786 of 2007) hereby
grants to:
PFIZER HEALTHCARE IRELAND
TRADING AS: PFIZER ANIMAL HEALTH, RINGASKIDDY, CO. CORK, IRELAND
an authorisation, subject to the provisions of the said Regulations and the general conditions of the attached authorisation, in respect of the
Veterinary Medicinal Product:
VANGUARD CPV
The particulars of which are set out in the attached Schedule. The authorisation is also subject to any special conditions as may be specified in
the Schedule.
The authorisation,unless revoked, shall continue in force from 30/08/2010.
Signed on behalf of the Irish Medicines Board
________________
A person authorised in that behalf by the said Board.
(NOTE: This authorisation replaces any previous authorisation in respect of this product which is now null and void.)
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 31/08/2010_
_CRN 7007027_
_page number: 1_
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Vanguard CPV
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Quantity per 1 ml dose
ACTIVE SUBSTANCE(S):
Live attenuated canine Parvovirus, strain NL-35-D, low passage, minimum : 10
7.0
CCID
50
*
*Cell culture infectious dose-50
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
The liquid is slightly turbid, reddish in colour.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs from 5 weeks of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of
Baca dokumen lengkap
